. 2017 Jan 3;91(2):e01793-16. doi: 10.1128/JVI.01793-16

TABLE 1.

Potential HLA-A*02:01-restricted epitopes selected from HSV VP13/14^a

Epitope	Sequence	Mol wt	No. of amino acids	IC₅₀ (nM)
Epitope	Sequence	Mol wt	No. of amino acids	BIMAS	SYFPEITHI	MAPPP	MHCPred	HLA-A*201
VP13/14_286–294	FLADAVVRL	1003.2	9	926.658	30	ND	0.41	5.6
VP13/14_374–382	ALLDRDCRV	1060.2	9	1055.1	25	0.7512	0.27	52
VP13/14_410–418	VLTREAAFL	1019.2	9	199.738	22	ND	0.43
VP13/14_417–425	FLGRVLDVL	1131.2	9	45.406	25	ND	0.38
VP13/14_464–472	ALPLGSPAV	823.9	9	69.552	26	0.5393	0.26
VP13/14_497–505	VLGAAVYAL	876.0	9	83.527	27	0.5307	0.45	100
VP13/14_504–512	ALHTALATV	896.0	9	159.97	30	0.6459	0.20	16
VP13/14_544–552	RLLGFADTV	991.1	9	479.172	27	0.6928	0.24	27
VP13/14_545–553	LLGFADTVV	934.1	9	48.478	21	ND	0.18
VP13/14_657–665	IMSQFRKLL	1,135.4	9	99.667	20	0.9931	0.42

The sequence of the HSV-1 tegument protein VP13/14 was submitted to screening for potential HLA-A*0201 epitopes using several computer algorithms. The 10 potential epitopes were selected on the basis of the HLA-A*0201-binding amino acid motifs. The predicted IC₅₀s were calculated by use of the (i) BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind) (ii) SYFPEITHI (http://www.syfpeithi.de/), (iii) MAPPP (http://www.mpiib-berlin.mpg.de/MAPPP), and (iv) MHCPred predictive computational algorithms, as described in Materials and Methods. The sequences of the peptide epitopes are based on the sequences of VP13/14 from HSV-1 strain 17. Sequences in bold are immunodominant epitopes from asymptomatic individuals. ND, not determined.